Tech Company Financing Transactions
EpicentRx Funding Round
Private investors participated in a $35 million Series D funding round for EpicentRx. The round was announced on 11/14/2019.
Transaction Overview
Company Name
Announced On
11/14/2019
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series D
Investors
Proceeds Purpose
The purpose of this funding round, which will be split into three tranches, is to progress the late-stage clinical development of EpicentRx's lead anticancer agent, RRx-001, and proprietary transgene-enhanced oncolytic adenoviral platform technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11099 North Torrey Pines Rd. 160
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Corey Carter
Chief Medical Officer
Bryan Oronsky
Chief Scientific Officer
Tony Reid
Vice President
Chris Larson
VP - General Counsel
Sarah Hibbard
VP - Operations
Scott Caroen
VP - Regulatory Affairs
Gina Varner
Browse more venture capital transactions:
Prev: 11/14/2019: Docker venture capital transaction
Next: 11/14/2019: wappier venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs